Boston Therapeutics, an innovator of drugs that target diabetes using complex carbohydrate chemistry, today announced the appointment of three management positions within its ranks. Effective immediately, Edward Shea will serve as Vice President Business Development, Tina M. Gagnon will serve as Consulting Director of Finance, and Yael T. Bobruff, Ph.D. will serve as Clinical Affairs Manager, respectively.
David Platt, Ph.D., Chief Executive Officer, Boston Therapeutics, said, "As Boston Therapeutics enters the next phase of its growth, it is imperative that we attract top talent to help us advance and commercialize our drug development programs. Ed Shea and Tina Gagnon's business and finance backgrounds, and Dr. Bobruff's expertise in biology and research significantly strengthen our management team. I am pleased they have decided to join our company, and I look forward to working with them in the months and years ahead."
Mr. Shea boasts of 25 years of experience in commercial development, marketing, and sales. Of that, 15 years of his experience includes business development, marketing, and sales leadership positions with GlaxoSmithKline and Salix Pharmaceuticals, as well as business development capacities with two startup biopharmaceutical companies, ViroPharma and Critical Therapeutics. Mr. Shea most recently worked with ViroPharma, Inc. as Sr. Eastern Area Sales Director. He holds a B.S. in Business/Marketing and an M.B.A. from Salve Regina University in Newport, RI.
Ms. Gagnon brings over 20 years of experience in finance. Most recently, she worked as Corporate Controller at Micronetics, Inc., at which she oversaw a staff responsible for accounts receivable, accounts payable, inventory management, and other activities. Beforehand, she served in the following capacities: Controller at Amherst Technologies, LLC; Assistant Controller of Fruit of the Loom's Sports & Licensing Division; and Senior Corporate Auditor at Standex International Corp. Ms. Gagnon holds a B.S. in Accountancy from Bentley College.
Most recently, Dr. Bobruff was a postdoctoral researcher in the Department of Systems Biology at Harvard University Medical School in Boston. There, she investigated in depth the genetic processes and mechanisms contributing to the evolution of host-pathogen interactions. Dr. Bobruff holds a B.Sc. in Biology from the Hebrew University of Jerusalem, a M.Sc. in Civil and Environmental Engineering, and a Ph.D. in Biological Science from Stanford University.
For more information, visit bostonti.com
MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com